Drake & Associates’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.11M Buy
8,082
+14
+0.2% +$3.59K 0.33% 24
2026
Q2
$2.03M Buy
8,068
+203
+3% +$43.7K 0.34% 23
2026
Q1
$1.71M Sell
7,865
-41
-0.5% -$9.1K 0.33% 25
2025
Q4
$1.81M Sell
7,906
-98
-1% -$22.3K 0.36% 34
2025
Q3
$1.73M Buy
8,004
+145
+2% +$29.5K 0.36% 44
2025
Q2
$1.46M Buy
7,859
+48
+0.6% +$8.92K 0.36% 40
2025
Q1
$1.64M Sell
7,811
-14
-0.2% -$2.72K 0.46% 32
2024
Q4
$1.49M Buy
7,825
+513
+7% +$94.3K 0.42% 27
2024
Q3
$1.44M Buy
7,312
+300
+4% +$56K 0.47% 20
2024
Q2
$1.2M Sell
7,012
-185
-3% -$30.6K 0.43% 21
2024
Q1
$1.31M Hold
7,197
– – 0.48% 21
2023
Q4
$1.12M Hold
7,197
– – 0.46% 21
2023
Q3
$1.07M Sell
7,197
-298
-4% -$43.7K 0.49% 21
2023
Q2
$1.01M Buy
7,495
+23
+0.3% +$3.37K 0.45% 22
2023
Q1
$1.19M Sell
7,472
-43
-0.6% -$6.57K 0.58% 18
2022
Q4
$1.21M Buy
+7,515
New +$1.15M 0.64% 18

Other funds holding ABBV

Drake & Associates's ABBV Position: Q3 2026 in Review

Drake & Associates increased its AbbVie (ABBV) stake by 0.17% in Q3 2026, buying an estimated $3.59K and bringing the position to 8,082 shares worth $2.11M. The position accounts for 0.33% of the portfolio, ranked #24.

Drake & Associates first reported a position in ABBV in Q4 2022 and has held it in 16 quarters since. 4,279 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Drake & Associates held 8,082 shares of AbbVie worth $2.11M as of Q3 2026.
  • Drake & Associates bought 14 AbbVie shares in Q3 2026, an estimated $3.59K.
  • AbbVie made up 0.33% of Drake & Associates's portfolio in Q3 2026, its #24 holding.
  • Drake & Associates first reported a position in AbbVie in Q4 2022 and has held it in 16 quarters since.
  • 4,279 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Drake & Associates's 13F filing for Q3 2026, filed 18 Nov 2026.